Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial
| Autor: | R. Roach, L. Carman, Ch. George, R. Rupert, L. R. Laufman, J.Ph. Kuebler, C. H. Spiridonidis, T. Patel, Timothy Moore, J. Jones, S. Blair, D. Colborn, J. Zangmeister |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment Docetaxel Neutropenia Vinorelbine Deoxycytidine Drug Administration Schedule Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Chemotherapy business.industry Hematology Middle Aged medicine.disease Chemotherapy regimen Survival Analysis Gemcitabine Surgery Treatment Outcome Drug Resistance Neoplasm Disease Progression Female Taxoids Neoplasm Recurrence Local business Febrile neutropenia medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 12(1) |
| ISSN: | 0923-7534 |
| Popis: | Summary Background Docetaxel and gemcitabine are active against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined with weekly gemcitabine in NSCLC patients failing one prior regimen Patients and methods Forty patients were enrolled Prior chemotherapy was a platinum-based combination in 36 patients, using vinorelbine in 26 patients and etoposide in 10 patients The other four patients had prior single agents Tumors were refractory or resistant to front-line therapy in 80% of patients Treatment was gemcitabine 800 mg/m2 days I, 8, 15 and docetaxel 100 mg/m2 day 1, with cycles repeated every four weeks Results Thirteen patients responded (32 5%, 95% confidence interval (CI) 19%—49%), including one complete and 12 partial responses. Responses were observed at all metastatic sites, with similar response frequencies in platinum-sens itive and platinum-resistant/refractory tumors The median time to progression for responders was nine months, with two responses lasting longer than a year Median survival was 8.1 months Hematologic toxicities included grade 4 neutropenia in 23 patients, with 4 episodes of febrile neutropenia, grade 3-4 thrombocytopenia in 9 patients, and anemia requiring red cell transfusions in 9 patients. With the exception of asthenia, severe non-hematologic toxicities were infrequent Conclusions Monthly docetaxel, combined with weekly gemcitabine, is an active and safe second-line therapy for NSCLC patients |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|